Clinical trial NCT01928680: Phase II Study of Capecitabine and Cisplatin to Treat Metastatic Triple Negative Breast Cancer
Official title: Phase II Study of Capecitabine and Cisplatin in Anthracycline and Taxanes-pretreated Metastatic Triple Negative Breast Cancer Patients
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Metastatic Breast Cancer
Keywords: Triple Negative Breast Cancer, Cisplatin, Capecitabine
Lead sponsor: ChineseAMS
Sponsor class: UNKNOWN
First posted: 2013-08-27
Enrollment: 33
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: It is a phase II trial to explore the efficacy and safety of cisplatin plus capecitabine in anthracycline and taxane-pretreated metastatic triple negative breast cancer patients.

Detailed description: Cisplatin contained regimens have been demonstrated to be effective in metastatic triple negative breast cancer patients in some phase II clinical trials. Meanwhile, Capecitabine is also a highly effective choice for metastatic breast cancer with considerable duration of response. Combination of cisplatin and capecitabine have been proved effective in metastatic breast cancer in several phase II trials. This study is aimed to investigate the efficacy and safety of this combination in triple negative breast cancer patients.

Eligibility criteria: Inclusion Criteria:

* Written and signed informed consent prior to beginning specific protocol procedures.
* Pathologically confirmed Estrogen Receptor(ER), Progesterone Receptor(PR) and Human Epidermal growth factor Receptor HER-2) negative ("triple negative") breast cancer and documented metastatic or locally advanced disease.

Measurable disease - with at least 1 lesion measurable by radiological method

* KPS\>=70
* 18 to 70 years old women
* Previously treated with an anthracycline and a taxane
* Hormone therapy for early-stage or metastatic breast cancer was permitted if hormonal receptor positive.
* Treatment with Herceptin for early-stage or metastatic breast cancer is permitted if HER2 positive
* Laboratory requirements:

  * Hematology Absolute neutrophil count\>=1,500 /μl; Platelets\>=100,000 /μl; Hemoglobin\>=10 g/dl
  * Liver function Total bilirubin\<=2 times ULN ASAT (SGOT) and ALAT (SGPT)\<=2.5 times UNL without liver metastasis or \<=5.0 times if liver metastasis Glucose\<=200 mg/dL
  * Renal function Serum creatinine\<=140 mol/l
* Life expectancy of at least 12 weeks
* Patients must be accessible for treatment and follow-up.
* Patients should have recovered from the acute reversible effects of prior treatment. This generally means at least 3 weeks should have elapsed since prior chemotherapy, adjuvant or Neoadjuvant treatment. and at least 4 weeks since prior (radical) radiotherapy or major surgery

Exclusion Criteria:

* Women who are pregnant or breast feeding
* History of brain and/or leptomeningeal metastases
* Past or current history of malignant neoplasm other than breast carcinoma, except for curatively treated non melanoma skin cancer, in situ carcinoma of the cervix or other cancer curatively treated and with no evidence of disease for at least 5 years
* Pre-existing neuropathy grade 1 according to the NCIC-CTC 3.0
* Psychiatric disorders or other conditions which would prevent pt. compliance
* Other serious illness or medical condition:
* Congestive heart failure, or unstable angina pectoris, previous history of myocardial infarction within 6 month prior to study entry, uncontrolled hypertension as determined by the Investigator or high risk uncontrolled, arrhythmia.
* History of significant neurological or psychiatric disorders including psychotic disorders, dementia of seizures that would prohibit the understanding and giving of informed consent.
* Active uncontrolled infection.
* Unstable peptic ulcer, unstable diabetes mellitus or other contraindication for the use of Corticosteroids.
* Inability to take and/or absorb oral medicine
* Prior treatment with capecitabine and/or cisplatin
* Concurrent treatment with other experimental drugs, or participation in another clinical trial with any investigational drug within 30 days prior to study entry

Primary outcomes:
measure: Overall Response Rate
timeFrame: 6 months
Secondary outcomes:
measure: Progression Free Survival
timeFrame: 2 years
measure: Overall Survival
timeFrame: 3 years
measure: Number and Severity of Adverse Events of Patients Enrolled in This Trial
timeFrame: 1 year
Other outcomes:
Locations:
city: Beijing
country: China
facility: Cancer Hospital, ChineseAMS
state: Beijing
Study officials:
affiliation: Chinese Academy of Medical Sciences
name: Binghe XU, MD, PHD
role: PRINCIPAL_INVESTIGATOR
References: